Boston (June 27, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market ("NASDAQ") that it was granted a hearing before a Nasdaq Hearings Panel (the "Panel"). This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq's no ...

Boston (May 20, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). This confirmation foll ...

Exhibit 99.1 Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding, - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 87-2147982 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRA ...

Core Insights - Allarity Therapeutics has achieved significant milestones in financial, regulatory, and clinical areas, particularly with the Phase 2 trial of stenoparib showing clear clinical benefits in advanced ovarian cancer patients [2][3][4] Financial Highlights - The company reported a cash balance of $14 million and stockholders' equity of $15 million, exceeding Nasdaq's minimum requirement of $2.5 million [3][4] - Research and Development (R&D) expenses for Q1 2024 were $2.2 million, an increase from $1.4 million in Q1 2023, primarily due to higher manufacturing costs and an extension fee [5] - General and Administrative (G&A) expenses decreased to $2.1 million in Q1 2024 from $2.2 million in Q1 2023 [5] - The net loss for Q1 2024 was $3.8 million, compared to $3.4 million in Q1 2023 [6] Clinical Developments - The Phase 2 trial of stenoparib was concluded early due to observed clinical benefits, including tumor shrinkage and long-term disease stability [3][4] - The company plans to prepare for a follow-on trial with FDA regulatory intent based on the promising results from the trial [3][4] Regulatory Compliance - Allarity has regained compliance with Nasdaq's Listing Rule 5550(a)(2) after executing a reverse stock split on April 9, 2024, maintaining a closing bid price above $1.00 for over ten consecutive trading days [3][4] - The company has requested the SEC to withdraw its Form S-1 registration, reflecting its improved financial outlook [2][3] Strategic Focus - Allarity has shifted its focus solely to the development of stenoparib, allowing for significant reductions in ongoing costs and better alignment with strategic priorities [4] - The company has deprioritized other projects, such as the development of IXEMPRA® and dovitinib, to concentrate resources on stenoparib [4]

Allarity Therapeutics, Inc. (ALLR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chan ...

- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced ...

- Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq's formal confirmation of compliance with equity requirements under the exchange's Rule 5550(b)(1). - Company will submit a request to the SEC to withdraw Form S-1 Boston (May 6, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its stockholders' e ...

Core Viewpoint - Allarity Therapeutics has announced the early discontinuation of its Phase 2 clinical trial for stenoparib, a novel PARP inhibitor, due to clear clinical benefits observed in heavily pre-treated ovarian cancer patients, allowing for a focus on developing a follow-on trial with FDA regulatory intent [1][2][3]. Group 1: Clinical Trial Details - The Phase 2 trial of stenoparib demonstrated significant clinical benefits, including tumor shrinkage and long-term disease stability in patients with advanced recurrent ovarian cancer [2]. - The decision to halt further enrollment in the trial is aimed at reallocating financial resources to expedite the development of a follow-on trial [3]. - The patients involved in the trial had undergone multiple prior treatments, often including PARP inhibitors, highlighting the effectiveness of stenoparib in this challenging patient population [3]. Group 2: Drug Response Predictor (DRP®) - Allarity employs its Drug Response Predictor (DRP®) to select patients with a high likelihood of benefiting from stenoparib based on their cancer's gene expression signature [7]. - The DRP® platform has shown its ability to predict clinical outcomes from drug treatment in cancer patients across numerous clinical studies [7]. Group 3: Company Commitment and Future Plans - Allarity is committed to rapidly analyzing trial data and plans to present comprehensive results in a clinical update [4]. - The early conclusion of the trial is seen as a significant milestone in the development of stenoparib, reflecting the company's dedication to addressing the urgent needs of advanced ovarian cancer patients [4]. - The company is focused on advancing stenoparib to meet significant unmet medical needs in cancer treatment [8].

Core Viewpoint - Allarity Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, which is a positive development for the company as it continues to focus on the clinical potential of its lead asset, stenoparib, for advanced ovarian cancer treatment [1][2]. Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients [3]. - The company utilizes its DRP® companion diagnostic for patient selection in its ongoing phase 2 clinical trial, NCT03878849 [3]. Compliance Achievement - On April 27, 2024, Allarity received formal notice from Nasdaq confirming that its stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days since April 9, 2024, thus meeting the requirements for regaining compliance with Nasdaq's Listing Rule 5550(a)(2) [1]. CEO's Statement - The CEO of Allarity expressed optimism regarding the clinical potential of stenoparib based on promising early data from the ongoing phase 2 trial and emphasized the company's commitment to addressing the urgent needs of advanced ovarian cancer patients [2].